title: All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
abstract: BACKGROUND
  Data are still conflicting on the indication of front-line autologous stem-cell transplantation (ASCT) as consolidation for aggressive lymphoma. To assess the therapeutic effect of ASCT among different aggressive lymphoma subtypes, we conducted a matched-control analysis by pooling the data from two Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
  
  
  METHODS
  Between October 1987 and September 1998, 330 patients received ASCT after achieving complete remission with the ACBVP induction regimen. The histological slides showed: B aggressive non-Hodgkin's lymphoma (B-NHL) in 249 patients (75%), T-NHL in 52 patients (15%) (including 23 T anaplastic) and non-classified NHL in 29 patients. The age-adjusted International Prognostic Index (aaIPI) was 2 or 3 in 66%. Patients were matched with controls from the same GELA database but treated with chemotherapy only.
  
  
  RESULTS
  ASCT did not benefit non-anaplastic T-NHL patients [5-year overall survival (OS) 44% (chemotherapy) versus 49% (ASCT), P=0.87; disease-free survival (DFS) 38% versus 45%, P=0.89] in comparison with B-NHL [5-year OS 77% (chemotherapy) versus 79% (ASCT), P=0.64; DFS 67% versus 72%, P=0.13]. However, for B-NHL patients with aaIPI score 2 or 3, the benefit of ASCT was significant.
  
  
  CONCLUSIONS
  This cohort study confirms the high efficacy of front-line ASCT in responding aggressive B-NHL patients with adverse prognostic factors.
authors.affiliation: Hôpital Saint Louis, AP-HP, Paris, France. nicolas.mounier@sls.ap-hop-paris.fr
authors.forename: N
authors.initials: N
authors.lastname: Mounier
authors.forename: C
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: J
authors.initials: J
authors.lastname: Brière
authors.forename: C
authors.initials: C
authors.lastname: Haioun
authors.forename: P
authors.initials: P
authors.lastname: Feugier
authors.forename: F
authors.initials: F
authors.lastname: Offner
authors.forename: C
authors.initials: C
authors.lastname: Recher
authors.forename: A
authors.initials: A
authors.lastname: Stamatoullas
authors.forename: F
authors.initials: F
authors.lastname: Morschhauser
authors.forename: M
authors.initials: M
authors.lastname: Macro
authors.forename: C
authors.initials: C
authors.lastname: Thieblemont
authors.forename: A
authors.initials: A
authors.lastname: Sonet
authors.forename: B
authors.initials: B
authors.lastname: Fabiani
authors.forename: F
authors.initials: F
authors.lastname: Reyes
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016022:Case-Control Studies; D002986:Clinical Trials as Topic; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D014182:Transplantation, Autologous; D016896:Treatment Outcome